DRMA Dermata Therapeutics, Inc.
$0.76▲ +5.15%
Healthcare
Other
Volume 186.9K
Avg Volume (10D) 17.52M
Key Metrics & Fundamentals
Market Cap
$3.74M
P/E Ratio
–
Div Yield
0.00%
52W Range
0.60 - 4.66
% vs 50 MA
-33.71%
% vs 200 MA
-43.42%
RSI-14
36.4
MACD Histogram
-0.0100
Beta (1Y vs SPY)
1.07
Free Cash Flow
-$2.53M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$3.01M
COGS
–
Operating Exp
$3.01M
Operating Income
-$3.01M
EBIT
-$3.01M
Pretax Income
-$2.97M
Net Income
-$2.97M
EPS (Diluted)
-0.74
Price & Volume History
Loading chart…
Recent News
BC-Most Active Stocks
Associated Press · Oct 15, 2026 10:30 AM ET
Dermata Therapeutics Announces Positive Topline Results from Cosmetic Study Evaluating Its Tome Foundational Treatment
ACCESS Newswire · Oct 15, 2026 8:05 AM ET
Papulopustular Rosacea Market Report Now Available, Covers 11 Countries Across North America, Europe, and Asia-Pacific, Profiling Galderma, Journey Medical, Dermata Therapeutics, and Dr. Reddy's Laboratories
GlobeNewswire · Aug 31, 2026 5:05 AM ET
Dermata Therapeutics Announces Commercial Launch of Tome Foundational Treatment
ACCESS Newswire · Aug 25, 2026 8:30 AM ET
Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch
ACCESS Newswire · Aug 21, 2026 8:30 AM ET
Dermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
ACCESS Newswire · Aug 17, 2026 8:30 AM ET
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026
ACCESS Newswire · Aug 11, 2026 4:05 PM ET
Dermata Therapeutics Announces Commercial Launch Date for Tome(TM) Foundational Treatment
ACCESS Newswire · Aug 5, 2026 8:30 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See DRMA's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.